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Abstract
The Knops blood group antigen erythrocyte polymorphisms have been associated with reduced
falciparum malaria-based in vitro rosette formation (putative malaria virulence factor). Having
previously identified single-nucleotide polymorphisms (SNPs) in the human complement receptor
1 (CR1/CD35) gene underlying the Knops antithetical antigens Sl1/Sl2 and McCa/McCb, we have
now performed genotype comparisons to test associations between these two molecular variants
and severe malaria in West African children living in the Gambia. While SNPs associated with Sl:
2 and McC(b+) were equally distributed among malaria-infected children with severe malaria and
control children not infected with malaria parasites, high allele frequencies for Sl 2 (0.800,
1365/1706) and McCb (0.385, 658/1706) were observed. Further, when compared to the Sl 1/
McCa allele observed in all populations, the African Sl 2/McCb allele appears to have evolved as a
result of positive selection (modified Nei–Gojobori test Ka−Ks/s.e. = 1.77, P-value <0.05). Given
the role of CR1 in host defense, our findings suggest that Sl 2 and McCb have arisen to confer a
selective advantage against infectious disease that, in view of these case–control study data, was
not solely Plasmodium falciparum malaria. Factors underlying the lack of association between Sl
2 and McCb with severe malaria may involve variation in CR1 expression levels.
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Nomenclature for the Knops blood group Swain–Langley has been updated at the International Society of Blood Transfusion
Nomenclature Committee meeting, 27th Congress of the ISBT, Vancouver, British Columbia as follows. The Swain–Langley-positive
phenotype and antigen previously referred to as Sl(a+) and Sla are now Sl:1 and Sl1, respectively; the allele Sla is now Sl 1. The
antithetical phenotype and antigen previously referred to as Vil+ and Vil are now Sl:2 and Sl2, respectively; the allele Vil, is now Sl 2.
Nomenclature for the Knops blood group, McCoy phenotype, antigen, and allele are McC(a+), McCa, McCa, and McC(b+), McCb,
McCb (Geoff Daniels, personal communication).
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Introduction
Rosette formation resulting from adhesion between Plasmodium falciparum-infected red
blood cells (RBC) and uninfected RBC is viewed as a critical in vitro marker of malaria
pathogenesis.1 Parasitized RBCs (pRBC) adhere to uninfected RBC (rosetting), other pRBC
(autoagglutination), and to endothelial cells lining blood vessels (cytoadherence). In
aggregate, it is clear that these adhesive interactions underlie P. falciparum sequestration and
are likely to contribute to the obstruction of blood flow and severe malaria. A number of
field studies have reported an association between in vitro rosette formation using patient’s
cells collected at the time of clinical presentation of malaria illness and cerebral malaria,1,2
severe malarial anemia,3,4 or both cerebral malaria and severe malarial anemia.5-8
Although exceptions to these findings have been reported,9,10 these observations are of
interest, as identifying host–parasite molecular partners underlying P. falciparum
sequestration may provide direction for developing strategies to block interactions linked to
severe malaria pathogenesis that contribute to millions of childhood deaths annually.
Serologic factors have been observed both to promote6,11-14 and disrupt1,2,5 in vitro
rosette formation. Additionally, several recent studies have uncovered a complex of
molecular relations involving the variant P. falciparum erythrocyte membrane protein
(PfEMP1) family of pRBC surface antigens and a number of different host cell surface
proteins in cellular adhesion assays. These studies have described ‘receptor–ligand’ relation
between regions of PfEMP1 and CD36, thrombospondin (TSP), intercellular adhesion
molecule-1 (ICAM-1),15,16 complement receptor 1 (CR1/CD35),17 platelet endothelial
adhesion molecule-1 (PECAM-1/CD31),18 blood group A,19 and heparan sulfate-like
molecules20 in a range of cellular adhesion interactions. Of further interest has been the
suggestion that these adhesive interactions may work synergistically to induce severe
malaria.4
Our recent studies have suggested that low CR1 expression and the Sl:2 phenotype
(previously known as Vil+21) are associated with reduced rosetting.17 The Sl:2 phenotype
may result from homozygosity for the Sl2 allele, presence of a nonexpressed Sl1 allele
(amorph), and/or reduced expression levels of the Sl1 allele that obscure serological typing
assays. Through identification of single-nucleotide polymorphisms SNPs in exon 2922 of
the CR1 gene, we recently correlated specific amino-acid substitutions in complement
control protein (CCP) module 25 (R1601G and K1590E) with Knops Sl:2 and McC(b+)
serologic phenotypes, respectively. Here, we have performed genotype comparisons to test
associations between these two molecular variants and severe malaria in a well-
characterized case–control study of West African children living in the Gambia.23
Results
Consistent with previous studies,22,24,25 we observed a significant elevation of the Sl2
(1601G) and McCb (1590E) alleles in the West African children (Sl2, 0.800, 1365/1706;
McCb, 0.386, 658/1706) compared to Caucasian (Sl2, 0.005, 1/200; McCb, 0.000, 0/200),
Asian (Sl2, 0.030, 6/198; McCb, 0.020, 4/198), and Hispanic Americans (Sl2, 0.030, 6/200;
McCb, 0.025, 5/200) (Sl2 Fisher’s exact test, P-value<0.0001; McCb Fisher’s exact test, P-
value<0.0001). Table 1 provides a comparison of genotype frequencies for these same
populations. Overall, alleles at both the Sl and McC loci were observed to be in Hardy–
Weinberg equilibrium (Sl χ2 (2 df)=0.079, P-value=0.674; McC χ2 (2 df)=0.005, P-
value=0.997) for the Gambian children studied here. As the amino-acid substitution at
position 1615 was not observed to influence serological recognition of either McCoy or
Swain–Langley antigens,22 and because all study subjects were either homozygous or
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heterozygous for the mutant allele (1615 V), this polymorphism was not considered in our
association studies.
Results in Table 2 show that neither Sl 2 nor McCb alleles separately, or the Sl 2/McCb
allele (data not shown) conferred protection against any of the severe malaria phenotypes
when malaria-infected children with disease were compared to children classified as ‘non-
malaria controls’ (children with mild, mostly infectious, illnesses who did not require
hospital admission and did not have any malaria parasites in their blood on microscopy).23
Children classified by a generalized phenotype of severe malaria were further characterized
by having one of cerebral malaria (unrousable coma score<3,26 or repeated seizures of >30
min), severe anemia (hemoglobin<5 g/dl on admission), or by a combined category
including death or disabling neurological sequelae when discharged from the hospital.27,28
For all comparisons, absence of association between the CR1CCP25 polymorphisms was
independent of hemoglobin S in beta globin genotypes (the most significant human
polymorphism conferring protection from severe malaria), and other potential confounders
(sex, ethnic group, location of residence) (data not shown).
When DNA and amino-acid sequence comparisons were performed among human and Pan
troglodytes CR1CCP25 haplotypes, we observed that all SNP led to amino-acid changes
(nonsynonymous mutations) in the human alleles, whereas three of four SNP observed in the
P. troglodytes CR1CCP25 coding sequence (GenBank Acc#. L24920)29 did not change the
amino-acid sequence (synonymous mutations). We then performed pairwise comparisons of
the human CR1CCP25 sequences (Figure 1) to determine if evidence for positive or
adaptive selection was observed. Results from a modified Nei–Gojobori test suggest that
positive selection underlies the accumulation of sequence changes differentiating
CR1CCP25Hs1 (Sl1/McCa; all human ethnic/geographic populations) and CR1CCP25Hs5
(Sl2/McCb; African-derived) (Modified Nei–Gojobori (Jukes–Cantor) test (Ka−Ks/s.e. =
0.023/0.013 = 1.77, P-value<0.05).30 Additional evidence supportive of positive selection
among human CR1CCP25 haplotypes was also obtained by the McDonald–Kreitman test31
(Fisher’s exact test, two-tailed P-value = 0.03). Together with results from our previous
study showing that the amino-acid substitutions at positions 1590 and 1601 are responsible
for the serological phenotype differences between McC(a+) vs McC(b+) and Sl:1 vs Sl:2,
respectively,22 evidence consistent with positive selection suggests that the CR1CCP25
polymorphisms have evolved to confer some form of selective advantage in African
populations.
Discussion
We observed a significant increase in the frequency of genetic polymorphisms associated
with the Knops blood group phenotypes Sl:2 and McC(b+) in the Gambian study population
living in malarious West Africa compared to non-African US-based populations. Despite the
striking increased frequency of Sl2 and McCb in the Gambian study population, we did not
observe an association between these African CR1 alleles and protection from severe
malaria phenotypes.
To interpret this result, it may be important to consider the influence of erythrocyte CR1
expression polymorphism on the Knops serologic and malaria disease phenotypes. During
our studies to identify DNA sequence polymorphisms associated with Sl:2 and McC(b+), we
showed that both heterozygosity for the CR1 K1590E (SNP A4795G) and R1601G (SNP
A4828G) amino-acid substitutions and erythrocyte CR1 expression polymorphism
contributed to genotype-Knops blood group phenotype discordance in 18% of Malians
studied.22 With this in mind, we examined further the associations between Sl and McC
genotypes and severe malaria by excluding heterozygous individuals from our analyses;
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however, again no significant associations between Sl2/McCb alleles and severe malaria
phenotypes were observed (data not shown).
Bellamy et al32 have surveyed the same Gambian population studied here for a CR1 intron
27 Hind III polymorphism associated with CR1 expression level differences to determine if
the low expression-associated allele would confer reduced susceptibility to severe malaria.
Although no significant association was observed between the HindIII low expression-
associated allele and protection from severe malaria,32 it is important to consider the
relationship between this polymorphism and CR1 expression in different ethnic groups.
While a number of studies have observed an association between the HindIII low-
expression-associated allele and reduced CR1 expression in Caucasians, Herrera et al33
found no association between this marker and CR1 expression in African Americans.
Similar lack of association between CR1 expression and the CR1 intron 27 Hind III
polymorphism has now been observed in a study population from Mali.34 Given the
observed inconsistencies between CR1 genetic and expression phenotype polymorphisms,
efforts to determine how erythrocyte CR1 expression differences contribute to in vitro
rosetting and severe malaria would require assessing erythrocyte CR1 density using freshly
collected blood samples not available for this retrospective study.
We have therefore confronted an interesting, but inevitable limitation of PCR-based field
investigations. PCR has enabled innumerable field studies once constrained by difficulties in
obtaining sufficient quantities and numbers of fresh blood samples, and by limited supplies
of antisera needed for blood group serology. Adhesion between pRBC and uninfected cells
may be influenced by amino-acid sequence polymorphism as well as differences in CR1
protein expression. Therefore, DNA-based studies may be limited in detecting associations
between critical molecular polymorphisms and disease-related phenotypes.
It will also be important to keep in mind the potentially complex molecular interactions
between the highly polymorphic P. falciparum ligand, PfEMP1, and CR1. The C3b binding
site (recognized by the mAb J3B11) has recently been identified as the region of CR1
necessary for P. falciparum rosetting.35 Interestingly, this region does not contain either Sl2
or McCb polymorphisms. Using a number of P. falciparum laboratory strains (n = 4) and
field isolates from Kenya (n = 15) and Malawi (n = 10), it was shown that blocking
interactions between erythrocyte-CR1 and P. falciparum-infected erythrocytes is
consistently efficacious in inhibiting rosette formation and therefore not limited to one
specific PfEMP1 sequence.35 Thus, although initial characterization of CR1-PfEMP1
involvement with in vitro rosette formation relied upon a portion of a single PfEMP1 allele,
this further study suggests that this host receptor–parasite ligand interaction may be a
common biological mechanism responsible for adhesion between P. falciparum-infected and
uninfected erythrocytes. Therefore, through an improved understanding of factors that might
inhibit erythrocyte-CR1–P. falciparum interactions in vitro, it may be possible to develop
therapeutic agents to limit or eliminate severe falciparum malaria pathogenesis.
Numerous microbial pathogens, in addition to P. falciparum, contribute to the infectious
burden on African populations. The worldwide distribution of the Sl1/McCa haplotype
suggests that this apparent ancestral allele may have been carried by human populations
migrating out of Africa between 60 000 and 100 000 years ago. The observed restriction of
the Sl2/McCb haplotype within African populations suggests that this haplotype has
emerged within African populations after this time period. Sequence comparisons between
the human and chimpanzee CR1CCP25 domains, in general, and between the CR1 Sl1/
McCa (all human ethnic/geographic populations) and Sl2/McCb (African-derived) domains
suggest that this region of CR1 and resulting conformations22 have evolved under adaptive
selection pressure. This hypothesis could be tested more completely after more extensive
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DNA sequence analysis of the human CR1 locus using linkage analysis approaches recently
described by Sabeti et al.36 Since Sl2/McCb appears to be advancing toward fixation in
African populations (Table 1), and considering the important role CR1 plays in regulating
immunity and host defense37 this polymorphism has probably been elevated in frequency
by infectious disease that, in view of these case–control study data, was not solely P.
falciparum malaria.
Methods
Sample preparation
Samples analyzed here have been described previously.23,38 Overall this was a hospital-
based case–control study of children categorized according to malaria infection/disease
severity as nonmalaria cases with other mild illnesses (nonmalaria controls; n = 390; average
age = 2.47 years) or cases of severe malaria (n = 463; average age = 3.43 years).23
Subgroups of severe included cerebral malaria (n = 331 average age = 3.78 years), severe
anemia (n = 152; average age = 2.19 years), and death or neurological sequelae (n = 98;
average age = 3.53 years). Differences observed for the number of individuals studied here
compared to previous studies arose based upon the availability of sufficient genomic DNA,
efficiency of PCR and resolution of CR1 genotyping assay results. Samples representing
North American ethnic groups have been described previously.38 Briefly, anonymous
donors were between 18 and 55 years of age and were classified by self-identified ethnicity.
No information regarding exposure to malaria parasites or other infectious diseases was
available. Sample collection from pediatric patients from the Gambia was performed
following protocols approved by the Gambian government/MRC joint ethical committee and
permission from each child’s parent or guardian. Sample collection from random blood
donors was performed following protocols approved by the American Red Cross.
CR1 genotyping using post-PCR multiplexed ligation detection reaction (LDR)
A 476 bp fragment of CR1 containing three polymorphic sites was PCR amplified using the
primers 5′-TAAAAAATAAGCTGTTTTACCATACTC and 5′-
CCCTCACACCCAGCAAAGTC (Figure 1). Amplifications were performed in a total
volume of 25 μl and contained 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1 mM MgCl2, 200 μM of
each dNTP, 0.2 μM of each primer, approximately 50 ng DNA, and 0.5 U of Amplitaq Gold
polymerase (Perkin-Elmer). To prevent polymerase extension during the subsequent LDR
procedure, residual polymerase activity was removed by incubation with 1/10 volume of 1
mg/ml proteinase K in 50 mM EDTA at 37°C for 30 min, 55°C 10 min. The proteinase K was
inactivated by incubation at 99°C for 10 min.
A set of three LDR probes consisting of two fluorescently labelled allelic and one common
probe was designed for each of the SNPs occurring at nucleotide positions 4795, 4828, and
4870 (Table 3, Figure 2). The common probes (100 pmol of each) were 5′ phosphorylated
in a volume of 100 μl using 10 U of T4 polynucleotide kinase and 1 mM ATP in 70 mM Tris-
HCl buffer pH 7.6 containing 10 mM MgCl2 and 5 mM dithiothreitol. After incubation at
37°C for 45 min, the T4 kinase was inactivated by the addition of 20 μg of proteinase K in
100 μl of TE buffer (10 mM Tris/HCl and 5 mM EDTA pH 8.0) and incubated at 37°C for 30
min. The proteinase K was inactivated by incubation at 99°C for 10 min.
Multiplexed LDR was performed in 15 μl volumes of 20 mM Tris-HCl buffer pH 7.6
containing 25 mM KCl, 10 mM MgCl2, 1mM NAD+, 10mM DTT, 0.1% Triton X-100, 10 nM
(200 fmol) of each LDR probe, 2 μl of PCR product, and 2 U of Taq DNA ligase. The
reactions were prepared on ice and then hot-started by placing on PCR blocks preheated to
95°C. An initial 1 min denaturation at 95°C was followed by 15 thermal cycles of
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denaturation at 95°C for 15 s, annealing and ligation at 68°C for 4 min. The activity of the
ligase was stopped after 15 cycles by cooling to 4°C and adding 2 μl of 100 mM EDTA.
Electrophoresis and detection of LDR products was performed on an ABI 3700 fluorescent
DNA sequencer. To 1 μl of LDR product was added 10 μl Hi Di formamide and 0.01 μl of
8 nM ABI Genescan-500 Rox size standards. Product sizes were calculated relative to the
standard by Genescan 3.5 using the second-order least-squares method. Automated allele
calling of LDR products was performed using Genotyper 2.5 and standardized by assays
performed on amplicons from cloned and sequenced allele-specific controls.
Hemoglobin (Hb) A/S genotyping
For individual samples lacking analysis of Hb A/S status, genotyping was performed
following methods developed by Husain et al.39 In these analyses, numerous samples
examined previously were included.23 All samples assayed in this, and the former study
produced results that were 100% concordant (data not shown).
Statistical analysis
χ2 and Fisher’s exact tests were performed using Stat View 5.0.1 or SAS 8.02 (SAS
Institute, Inc., Cary, NC, USA). Tests comparing nonsynonymous (amino-acid changing;
Ka) SNPs vs synonymous (amino-acid non-changing; Ks) between allele-specific sequences
were performed using MEGA2 (http://www.megasoftware.net).30 Briefly, modified Nei–
Gojobori (Jukes–Cantor) tests were performed for all pairwise sequence comparisons among
the human haplotypes reported in Figure 1 to determine the difference (Ka−Ks); standard
errors (s.e.) were computed based upon 1000 bootstrap replicates. A further one-tailed Z-test
(D/σ) was performed to determine the significance of each pairwise difference: Ka−Ks/(s.e.)
where a score ≥1.6 attains a P-value of <0.05. An additional test of positive/adaptive
selection was conducted by performing a McDonald–Kreitman test comparing the five
human CR1CCP25 haplotypes with that for P. troglodytes (GenBank Acc# L24920).29 This
test was performed using DnaSP 3.53 (http://www.ub.es/dnasp).40
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Figure 1.
Amino-acid sequence alignment comparing CR1CCP25 (Hs) alleles. Standard single-letter
nomenclature illustrates the amino-acid sequence for five human CR1CCP25 alleles. This
sequence is inclusive of amino acids 1587–1648. Amino-acid identity is represented by a
dash (-); polymorphic positions are identified by a variant amino-acid symbol compared to
the CR1CCP25Hs1 reference sequence. GenBank accession numbers for each of the human
CR1CCP25 alleles include AF264716 (CRlCCP25Hs1), AF264715 (CR1CCP25Hs2),
L17408 (CR1CCP25Hs3), AF169969 (CR1CCP25Hs4), and AF169970 (CR1CCP25Hs5).
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Figure 2.
Post-PCR ligase detection reaction (LDR) genotyping assay.
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